Evaluation of Using Different Screwed Abutment Height
Study Details
Study Description
Brief Summary
A prospective randomized controlled clinical trial will be conducted. Study groups will be assigned as described above. The patients will be randomly divided into two groups in order to study the influence of prosthetic screw abutment in marginal bone loss (MBL) around Bone Level Tapered implants (BLT® Roxolid® SLActive® guided implants, Straumann Dental Implant System, Institut Straumann AG, Basel, Switzerland).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
48 patients will be selected with partial edentulism in the maxilla or mandible, requiring two dental implants in the posterior areas (molars and premolars).
Each patient will be randomly allocated in one of the two groups: test group (n=36) or control group (n=12) and all the implants will be placed by residents of the International Master in Oral Surgery and Master in Periodontics of the same University.
Study groups
Group 1: Two stage approach (cover screw in first surgery and healing abutment in second surgery) (12 patients)
Group 2: One stage approach (healing cap over trans-epithelial abutments) (36 patients).Two subgroups according to different trans-epithelial height abutment:
-
Subgroup 2.1: Screw-retained abutment of 1 mm height (18 patients)
-
Subgroup 2.2: Screw-retained abutment of 2.5 mm height (18 patients)
Clinical Parameters and Outcomes
-
Three-dimensional volumetric changes in hard and soft tissues (Cone-beam computed tomography superposed with digital cast models).
-
Marginal bone level (MBL) change: Standardized intraoral periapical x-rays will be taken on the day of surgery, 4, 6, 12, 24 and 36 months following surgery.
-
Probing depth, bleeding on probing and keratinized mucosa width will be measured in the follow-up visits in 3 different points in buccal (Mesial, center and distal).
-
VAS Scale: The visual analog scale or visual analog scale (VAS).
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: Control group Group 1: 2 stage approach (cover screw) (12 patients): cover screw is placed over the dental implants in the first surgery and a second surgery will be performed to expose the implants and placing a healing abutment after 2-4 months, DEVICES: COVER SCREW (first surgery) and HEALING ABUTMENT (second surgery) |
Device: Dental implant placement with COVER SCREW (two surgeries in control group) or DEFINITIVE TRANSEPITHELIAL ABUTMENT (one surgery in test group)
Dental implant placement using cover screws (first surgery) and a healing abutment (second surgery) or definitive transepithelial abutments the same day of the implant placement (one unit surgery)
|
| Experimental: Test group Group 2: Protective plastic cap over different definitive trans-epithelial abutments are placed in the unic surgery performed (36 patients): Definitive transepithelial abutments will be placed the same day of the implant placement surgery. DEVICE: DEFINITIVE TRANSEPITHELIAL ABUTMENT |
Device: Dental implant placement with COVER SCREW (two surgeries in control group) or DEFINITIVE TRANSEPITHELIAL ABUTMENT (one surgery in test group)
Dental implant placement using cover screws (first surgery) and a healing abutment (second surgery) or definitive transepithelial abutments the same day of the implant placement (one unit surgery)
|
Outcome Measures
Primary Outcome Measures
- Marginal bone loss [After implant loading (baseline)and once every year to 36 months follow-up]
Periimplant bone level by measuring from the implant platform to the first bone to implant contact. Messuret in 2 points: MESIAL AND DISTAL with intra-oral XR. (measured in millimeters)
Secondary Outcome Measures
- Probing depth [After implant loading (baseline)and once every year to 36 months follow-up]
Measuring this outcomes at 4 different points .(Mesial Buccal, Center Buccal, Distal Buccal and central lingual) (measured in millimeters).
- Bleeding on probing [After implant loading (baseline)and once every year to 36 months follow-up]
Measuring this outcomes at 4 different points .(Mesial Buccal, Center Buccal, Distal Buccal and central lingual) (measured in millimeters).
- Keratinized mucosa width [After implant loading (baseline)and once every year to 36 months follow-up]
Measuring this outcomes at 4 different points .(Mesial Buccal, Center Buccal, Distal Buccal and central lingual) (measured in millimeters).
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Signed informed consent
-
Overall, healthy subjects
-
Females and males of at least eighteen-years
-
Requiring a minimum of two implants (molar and/or premolar teeth)
-
Adequate oral hygiene (less than 15% FMPS)
-
Able to follow instructions and attend a regular compliance
-
Enough bone to place a standard implant of 4.1 mm diameter.
Exclusion Criteria:
-
Acute local infection
-
Occlusal overload with parafunctional activity (assessed clinically)
-
Large occlusal discrepancies
-
Untreated periodontal disease assessed by Socransky et al. parameters (≥2mm clinical attachment loss in two consecutive visits within 1 year)
-
Smokers (more than 10 cigarettes/day)
-
Drug and/or alcoholic dependencies
-
Medical conditions contraindicating implant surgery
-
History of head and/or neck radiation
-
Bisphosphonate therapy
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Universitat Internacional de Catalunya | Barcelona | Spain | 08195 |
Sponsors and Collaborators
- Universitat Internacional de Catalunya
Investigators
- Principal Investigator: Jordi Gargallo-Albiol, Universitat Internacional de Catalunya
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CIR-ECL-2016-03